As an academic pediatric oncologist in the field for the last 30 years, I have seen first hand the difference we have made in the lives of our patients and their families!
Federal funding has been critical in the war against cancer and at the cost of $326 per life year saved! There is no wastage here but great implications for the health of society which as we know today. https://t.co/kHJhWYUa4X
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors | Journal of Clinical Oncology https://t.co/sU3GA3C3B4 @mascarleo @CSCancerCenter @GuerinChildrens@JCO_ASCO#pedcsm#scmsm
@Naturecancer has released a Research Briefing on our #MolecularTwin paper! I’m very glad the editors chose to summarize our work on an innovative #PrecisionOncology platform for #PancreaticCancer so this research can be shared with a wider audience.
https://t.co/QiDowBsKa4
An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy @janeway_MD@JanewayLab, @AlannaChurch_MD
https://t.co/SuFi8gr1jN
Patrick grohar presenting @SARCtrials SARC037 use of trabectedin in #Ewing#Sarcoma w irinotecan and 28f-FLT imaging. Strong scientific rarionale. #ASCO22
Cohort study validated CHIC-HS in an independent cohort of #hepatoblastoma patients. Data on the contribution of hepatoblastoma histologic subtype to risk stratification were also generated. @szhou53 @mascarleo@ChildrensLA https://t.co/Br1bK9nhRq